Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29207184 | 0.78 | GAA (0.39) | GAAALDH1A1CYP3A4MAPTCYP2D6 | |
| Guanidine SCHEMBL27275385 | 0.75 | GAA (0.41) | GAAALDH1A1LMNAALOX15BLM | |
| SCHEMBL21018733 | 0.75 | GAA (0.41) | GAAALDH1A1CYP2D6 | |
| SCHEMBL28243058 | 0.75 | GAA (0.41) | GAAALDH1A1CYP2D6 | |
| Guanidine SCHEMBL28290227 | 0.73 | GAA (0.39) | GAAALDH1A1LMNAALOX15BLM | |
| Guanidine SCHEMBL27900572 | 0.73 | GAA (0.39) | GAAALDH1A1LMNAALOX15BLM | |
| SCHEMBL8279446 | 0.71 | — | — | |
| SCHEMBL4816898 | 0.71 | — | — | |
| SCHEMBL27700402 | 0.70 | GAA (0.41) | GAAALDH1A1LMNA | |
| Acetamide SCHEMBL28017647 | 0.69 | LMNA (0.47) | GAAALDH1A1CYP2D6LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103946221-B | heterocyclic compounds for the treatment of cystic fibrosis | 诺华股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-103946221-A | Heterocyclic compounds for the treatment of cystic fibrosis | NOVARTIS AG | 2014-07-23 | — | — | CN | disclosed |